

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious and rare diseases:

## Oncology

Drug Class	Platform	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights/Collaborator	
mRNA	FixVac (fixed combination of shared cancer antigens)	BNT111	Advanced melanoma (Adjuvant & Metastatic)	██████████	██████████	██████████		Fully-owned	
		BNT112	Prostate cancer	██████████	██████████			Fully-owned	
		BNT113	HPV16+ head and neck cancer <sup>1</sup>	██████████	██████████	██████████		Fully-owned	
		BNT115	Ovarian cancer <sup>1</sup>	██████████	██████████			Fully-owned	
		BNT116	NSCLC	██████████				Fully-owned	
	iNeST (patient specific cancer antigen therapy)	autogene cevumeran (BNT122)	1L melanoma	██████████	██████████	██████████		Genentech (global 50:50 profit/loss share)	
			Adjuvant colorectal cancer	██████████	██████████	██████████			
			Solid tumors	██████████	██████████				
	Intratumoral Immunotherapy	SAR441000 (BNT131)	Solid tumors ( <i>IL-12sc</i> , <i>IL-15sushi</i> , <i>GM-CSF</i> , <i>IFNα</i> )	██████████	██████████			Sanofi (global profit/loss share)	
	RiboMabs (mRNA-encoded antibodies)	BNT141	Multiple solid tumors	██████████				Fully-owned	
		BNT142	Multiple solid tumors ( <i>CD3+CLDN6</i> )	██████████				Fully-owned	
	RiboCytokines (mRNA-encoded cytokines)	BNT151	Multiple solid tumors ( <i>Optimized IL-2</i> )	██████████	██████████			Fully-owned	
		BNT152, BNT153	Multiple solid tumors ( <i>IL-7, IL-2</i> )	██████████	██████████			Fully-owned	
	Cell Therapies	CAR-T Cells	BNT211	Multiple solid tumors ( <i>CLDN6</i> )	██████████	██████████			Fully-owned
			BNT212	Pancreatic, other cancers ( <i>CLDN18.2</i> )	██████████				Fully-owned
Neoantigen-based T cell therapy		BNT221 (NEO-PTC-01)	Multiple solid tumors	██████████	██████████			Fully-owned	
TCRs		To be selected	All tumors	██████████				Fully-owned	
Antibodies	Next-Gen CP <sup>2</sup> Immunomodulators	GEN1046 (BNT311)	Multiple solid tumors ( <i>PD-L1×4-1BB</i> )	██████████	██████████			Genmab (global 50:50 profit/loss share)	
		GEN1042 (BNT312)	Multiple solid tumors ( <i>CD40×4-1BB</i> )	██████████	██████████				
	Targeted Cancer Antibodies	BNT321 (MVT-5873)	Pancreatic cancer ( <i>sLea</i> )	██████████	██████████			Fully-owned	
SMIM <sup>3</sup>	Toll-Like Receptor Binding	BNT411	Solid tumors ( <i>TLR7</i> )	██████████	██████████			Fully-owned	

## Infectious Diseases

Drug Class	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Commercial	Rights/Collaborator
mRNA	BNT162b2	COVID-19	██████████	██████████	██████████	██████████	██████████	Fosun Pharma (China), Pfizer (Global, except China)
	BNT161	Seasonal influenza	██████████	██████████				Pfizer
	Un-named program	Malaria	██████████					Fully-owned
	Un-named program	HIV	██████████					Bill & Melinda Gates Foundation
	Un-named program	Tuberculosis	██████████					Bill & Melinda Gates Foundation
	5 un-named programs	Undisclosed indications	██████████					Fully-owned
Antibodies	Undisclosed program	COVID-19	██████████					Fully-owned

<sup>1</sup> BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials

<sup>2</sup> Checkpoint Inhibitor

<sup>3</sup> Small Molecule Immunomodulators